Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹13.02 Cr |
| Reserved for Market Maker | ₹0.66 Cr |
| Net Issue Size | ₹13.02 Cr |
| Fresh Issue | ₹12.36 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹65.00-70.00 per share |
| BSE Code | 544529 |
| Registrar | Bigshare Services Pvt.Ltd. |
| Lead Managers | Interactive Financial Services Ltd. |
| Allotment Status | |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 4,000 shares · Multiples of 2,000 shares
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing, and distribution of finished pharmaceutical formulations
The company manufactures and distributors of a broad range of pharmaceutical formulations covering multiple therapeutic areas: antacids & PPIs, pain management, anti-inflammatories, antibiotics, cardiology & antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, sachets, and more.
Products:
As of March 31, 2025, the company has 194 pharmaceutical formulations in more than eleven therapeutic segments.
Its warehouse is located over 15,732 sq. Feet and 1989 sq. feet in Ahmedabad, Gujarat. Its distribution model includes 125 direct and sub distributors and a sales team of 54 field personnel.
As of March 31, 2025, the company had 70 employees.
Competitive Strengths
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital Expenditure for Office Premises with furniture and Industrial Racks | 1.63 |
| 2 | Working Capital | 8.00 |
| 3 | General Corporate Purposes | 1.91 |
| 4 | Issue Expenses | 1.48 |
| Total | 13.02 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 21.92 | 10.03 | 6.22 |
| Total Income | 24.64 | 17.88 | 13.90 |
| Profit After Tax | 3.10 | 0.80 | 0.19 |
| EBITDA | 4.76 | 1.49 | 0.57 |
| NET Worth | 6.97 | 1.77 | 0.97 |
| Reserves and Surplus | 1.97 | 1.47 | 0.67 |
| Total Borrowing | 10.36 | 5.31 | 2.21 |
| Amount in ₹ Crore | |||
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 44.50% |
| ROCE | 45.66% |
| Debt / Equity | 1.49% |
| RoNW | 44.50% |
| PAT Margin | 12.62% |
| EBITDA Margin | 19.31% |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 6.20 | 4.52 |
| P/E (x) | 11.29 | 15.49 |
| Promoter Holding | 100% | 72.89% |
| Market Cap | ₹48.02 Cr. | |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead Manager Fees including Underwriting Commission | 0.93 |
| 2 | Brokerage, selling commission and Marketing | 0.21 |
| 3 | Registrar to the Issue | 0.01 |
| 4 | Legal Advisors | 0.02 |
| 5 | Advertising and marketing expenses | 0.07 |
| 6 | Regulators including stock exchanges | 0.08 |
| 7 | Printing and distribution of issue stationary | 0.04 |
| 8 | Others (Market Making fees etc.) | 0.12 |
Last Updated on 03-Jul-2026 10:38:48
